Skip to content
OpenCapital
Get started

Pfizer PFE International Developed Markets — Revenues:

Other geography segments

International Emerging Markets
$2.29B+6.0%

Other financials

Income statement

See full
Revenue$14.5B+5.4%
Gross profit$10.9B+0.3%
Net income$2.7B-9.4%
EPS (diluted)$0.47-9.6%

Balance sheet

See full
Cash & equivalents$1.8B+18.8%
Total debt$64.4B+5.0%
Total equity$90.1B-0.3%
Total assets$207.62B-0.2%

Cash flow

See full
Operating cash flow$2.6B+12.0%
CapEx$436.0M-22.7%
Free cash flow$2.2B+23.0%

Valuation

See full
Market cap$143.68B+11.1%
Enterprise value$206.35B+9.2%
P/E11.9×—
P/S2.3×+0.2×

Profitability

See full
Gross margin73.5%+1.2pp
Net margin15.7%—

Returns & leverage

See full
Return on equity10.6%—
Debt / equity0.7×0.0×
Current ratio1.2×0.0×

Where this comes from

Reported directly by Pfizer in its filing.

Tagged under the XBRL concept us-gaap:Revenues.

The official record: Pfizer’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Pfizer's international developed markets — revenues:.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Pfizer's international developed markets — revenues:?
Pfizer (PFE) reported international developed markets — revenues: of $3.43B in Q1 2026.
How has Pfizer's international developed markets — revenues: changed year-over-year?
Pfizer's international developed markets — revenues: increased by 7.8% year-over-year, from $3.18B to $3.43B.
What is the long-term trend for Pfizer's international developed markets — revenues:?
Over 3 years (2022 to 2025), Pfizer's international developed markets — revenues: has grown at a -26.4% compound annual growth rate (CAGR), from $40.53B to $16.19B.
What does international developed markets — revenues: mean?
Total revenue earned from pharmaceutical sales in mature, high-income international markets.
How do you interpret international developed markets — revenues:?
An increase suggests successful product launches and strong demand in established global markets, while a decrease may indicate competitive pressure, patent expirations, or unfavorable currency fluctuations.
How does international developed markets — revenues: compare across companies?
Peers in the pharmaceutical industry typically report similar geographic segments, often categorized as 'International' or 'Rest of World' developed markets, allowing for benchmarking of global commercial execution.